Novartis looks set to repurpose cancer drug in MS after tria...

Novartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use in multiple sclerosis, with plans for regulatory filings later this year.

Tackling the remaining challenges of multiple sclerosis

With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest

Novartis ups 2019 guidance after strong Q2

Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis drug Cosentyx being the star performer.

Understanding Multiple Sclerosis

Informative downloadable pack on Multiple Sclerosis

Novartis secures initial block on Gilenya generics in US

Celgene gets MS blockbuster-in-waiting ozanimod back on trac...

Regulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple sclerosis, setting up verdicts next year.